Mir-582-3p and Mir-582-5p Suppress Prostate Cancer Metastasis to Bone by Repressing TGF-β Signaling.
Shuai Huang,Changye Zou,Yubo Tang,Qingde Wa,Xinsheng Peng,Xiao Chen,Chunxiao Yang,Dong Ren,Yan Huang,Zhuangwen Liao,Sheng Huang,Xuenong Zou,Jincheng Pang
DOI: https://doi.org/10.1016/j.omtn.2019.01.004
IF: 10.183
2019-01-01
Molecular Therapy — Nucleic Acids
Abstract:A number of studies have reported that aberrant expression of microRNAs (miRNAs) closely correlates with the bone metastasis of prostate cancer (PCa). However, clinical significance and functional roles of both strands of a single miRNA in bone metastasis of PCa remain undefined. Here, we reported that miR-582-3p and miR-582-5p expression were simultaneously reduced in bone metastatic PCa tissues compared with non-bone metastatic PCa tissues. Downexpression of miR-582-3p and miR-582-5p strongly and positively correlated with advanced clinicopathological characteristics and shorter bone metastasis-free survival in PCa patients. Upregulating miR-582-3p and miR-582-5p inhibited invasion and migration abilities of PCa cells in vitro, as well as repressed bone metastasis in vivo. Our results further revealed that miR-582-3p and miR-582-5p attenuated bone metastasis of PCa via inhibiting transforming growth factor beta (TGF-beta) signaling by simultaneously targeting several components of TGF-beta signaling, including SMAD2, SMAD4, TGF-beta receptor I (TGFBRI), and TGFBRII. Moreover, deletion contributes to miR-582-3p and miR-582-5p downexpression in PCa tissues. Finally, clinical negative correlations of miR-582-3p and miR-582-5p with SMAD2, SMAD4, TGFBRI, and TGFBRII were demonstrated in PCa tissues. Thus, our findings explore a novel tumor-suppressive miRNA with its both strands implicated in bone metastasis of PCa, suggesting its potential therapeutic value in treatment of PCa bone metastasis.